Limits...
ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas

View Article: PubMed Central - PubMed

ABSTRACT

The A disintegrin and metalloproteinase 9 (ADAM9) protein has been suggested to promote carcinoma invasion and appears to be overexpressed in various human cancers. However, its role has rarely been investigated in gliomas and, thus, in the current study we have evaluated ADAM9 expression in gliomas and examined the relevance of its expression in the prognosis of glioma patients. Clinical characteristics, RNA sequence data, and the case follow-ups were reviewed for 303 patients who had histological, confirmed gliomas. The ADAM9 expression between lower-grade glioma (LGG) and glioblastoma (GBM) patients was compared and its association with progression-free survival (PFS) and overall survival (OS) was assessed to evaluate its prognostic value. Our data suggested that GBM patients had significantly higher expression of ADAM9 in comparison to LGG patients (p < 0.001, t-test). In addition, among the LGG patients, aggressive astrocytic tumors displayed significantly higher ADAM9 expression than oligodendroglial tumors (p < 0.001, t-test). Moreover, high ADAM9 expression also correlated with poor clinical outcome (p < 0.001 and p < 0.001, log-rank test, for PFS and OS, respectively) in LGG patients. Further, multivariate analysis suggested ADAM9 expression to be an independent marker of poor survival (p = 0.002 and p = 0.003, for PFS and OS, respectively). These results suggest that ADAM9 mRNA expression is associated with tumor grade and histological type in gliomas and can serve as an independent prognostic factor, specifically in LGG patients.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier survival analysis of different grades of glioma patients based on ADAM9 expression. (A) Comparison of the PFS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (B) Comparison of the OS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (C) Comparison of the PFS between ADAM9 high and low expression group in patients with GBMs (p = 0.994, log-rank test); (D) Comparison of the OS between ADAM9 high and low expression group in patients with GBMs (p = 0.656, log-rank test). PFS, Progression-free survival; OS, overall survival; LGG, lower-grade glioma; GBM, glioblastoma.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5037653&req=5

ijms-17-01276-f003: Kaplan–Meier survival analysis of different grades of glioma patients based on ADAM9 expression. (A) Comparison of the PFS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (B) Comparison of the OS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (C) Comparison of the PFS between ADAM9 high and low expression group in patients with GBMs (p = 0.994, log-rank test); (D) Comparison of the OS between ADAM9 high and low expression group in patients with GBMs (p = 0.656, log-rank test). PFS, Progression-free survival; OS, overall survival; LGG, lower-grade glioma; GBM, glioblastoma.

Mentions: To determine the association between ADAM9 mRNA expression and clinical outcomes, the data from the cohort of 303 glioma patients was analyzed. The mean follow-up time of the glioma patients was 25.8 ± 21.8 months (range 0.7–83.0 months; median, 17.2 months). In total, 141 patients died during the follow-up time (65.2% males). The Kaplan–Meier analysis showed that there was a significant difference in both progression-free survival (PFS, p < 0.001, log-rank test, Figure 3A) and overall survival (OS, p < 0.001, log-rank test, Figure 3B) between the LGG patients having high or low ADAM9 expression. The LGG patients with low ADAM9 expression were observed to have a better survival than those with high ADAM9 expression. In contrast, no significant differences were observed with respect to either PFS or OS in GBM patients, based on ADAM9 expression levels (p = 0.994 and 0.656, log-rank test, PFS and OS, respectively, Figure 3C,D). This result indicated that ADAM9 expression can serve as a potential prognostic factor for at least LGG patients.


ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas
Kaplan–Meier survival analysis of different grades of glioma patients based on ADAM9 expression. (A) Comparison of the PFS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (B) Comparison of the OS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (C) Comparison of the PFS between ADAM9 high and low expression group in patients with GBMs (p = 0.994, log-rank test); (D) Comparison of the OS between ADAM9 high and low expression group in patients with GBMs (p = 0.656, log-rank test). PFS, Progression-free survival; OS, overall survival; LGG, lower-grade glioma; GBM, glioblastoma.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5037653&req=5

ijms-17-01276-f003: Kaplan–Meier survival analysis of different grades of glioma patients based on ADAM9 expression. (A) Comparison of the PFS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (B) Comparison of the OS between ADAM9 high and low expression group in patients with LGG tumors (p < 0.001, log-rank test); (C) Comparison of the PFS between ADAM9 high and low expression group in patients with GBMs (p = 0.994, log-rank test); (D) Comparison of the OS between ADAM9 high and low expression group in patients with GBMs (p = 0.656, log-rank test). PFS, Progression-free survival; OS, overall survival; LGG, lower-grade glioma; GBM, glioblastoma.
Mentions: To determine the association between ADAM9 mRNA expression and clinical outcomes, the data from the cohort of 303 glioma patients was analyzed. The mean follow-up time of the glioma patients was 25.8 ± 21.8 months (range 0.7–83.0 months; median, 17.2 months). In total, 141 patients died during the follow-up time (65.2% males). The Kaplan–Meier analysis showed that there was a significant difference in both progression-free survival (PFS, p < 0.001, log-rank test, Figure 3A) and overall survival (OS, p < 0.001, log-rank test, Figure 3B) between the LGG patients having high or low ADAM9 expression. The LGG patients with low ADAM9 expression were observed to have a better survival than those with high ADAM9 expression. In contrast, no significant differences were observed with respect to either PFS or OS in GBM patients, based on ADAM9 expression levels (p = 0.994 and 0.656, log-rank test, PFS and OS, respectively, Figure 3C,D). This result indicated that ADAM9 expression can serve as a potential prognostic factor for at least LGG patients.

View Article: PubMed Central - PubMed

ABSTRACT

The A disintegrin and metalloproteinase 9 (ADAM9) protein has been suggested to promote carcinoma invasion and appears to be overexpressed in various human cancers. However, its role has rarely been investigated in gliomas and, thus, in the current study we have evaluated ADAM9 expression in gliomas and examined the relevance of its expression in the prognosis of glioma patients. Clinical characteristics, RNA sequence data, and the case follow-ups were reviewed for 303 patients who had histological, confirmed gliomas. The ADAM9 expression between lower-grade glioma (LGG) and glioblastoma (GBM) patients was compared and its association with progression-free survival (PFS) and overall survival (OS) was assessed to evaluate its prognostic value. Our data suggested that GBM patients had significantly higher expression of ADAM9 in comparison to LGG patients (p &lt; 0.001, t-test). In addition, among the LGG patients, aggressive astrocytic tumors displayed significantly higher ADAM9 expression than oligodendroglial tumors (p &lt; 0.001, t-test). Moreover, high ADAM9 expression also correlated with poor clinical outcome (p &lt; 0.001 and p &lt; 0.001, log-rank test, for PFS and OS, respectively) in LGG patients. Further, multivariate analysis suggested ADAM9 expression to be an independent marker of poor survival (p = 0.002 and p = 0.003, for PFS and OS, respectively). These results suggest that ADAM9 mRNA expression is associated with tumor grade and histological type in gliomas and can serve as an independent prognostic factor, specifically in LGG patients.

No MeSH data available.


Related in: MedlinePlus